Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans

References

• Bailey CJ. (2011). Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63–71.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–69.
   PubMed Web of Science ®Google Scholar
• Chen LZ, Jungnik A, Mao Y, et al. (2014). Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica 45:520–9.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court MH, Hazarika S, Akhlaghi F. (2011). Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 39:448–55.
   PubMed Web of Science ®Google Scholar
• Edwards RJ, Adams DA, Watts PS, et al. (1998). Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377–87.
   PubMed Web of Science ®Google Scholar
• Elkinson S, Scott LJ. (2013). Canagliflozin: first global approval. Drugs 73:979–88.
   PubMed Web of Science ®Google Scholar
• Engel G, Hofmann U, Heidemann H, et al. (1996). Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613–23.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. (2013). Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36:1260–5.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–97.
   PubMed Web of Science ®Google Scholar
• Freeman JS. (2013). Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 125:214–26.
   PubMed Web of Science ®Google Scholar
• Furlan V, Demirdjian S, Bourdon O, et al. (1999). Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther 289:1169–75.
   PubMed Web of Science ®Google Scholar
• Haneda M, Yutaka S, Sasaki S, et al. (2012). The Effect of Luseogliflozin (TS-071), a Selective SGLT2 inhibitor, on Pharmacodynamics and Pharmacokinetics in Japanese Type 2 Diabetic Subjects with Renal Impairment. American Diabetes Association 72nd Scientific Session, Philadelphia, PA, USA, Jun 8-12, 2012. Poster Session 1062-P.
   Google Scholar
• Hasegawa M, Chino Y, Horiuchi N, et al. (2015). Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent. Xenobiotica 45:1105–15.
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Hiroi T, et al. (2001). cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun 280:1135–41.
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Mise M, et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298–304.
   PubMed Web of Science ®Google Scholar
• Hsu MH, Savas U, Griffin KJ, Johnson EF. (2007). Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39:515–38.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Hanley WD, Petry AS, et al. (2009). Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 53:1747–52.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zollinger M, Borell H, et al. (2011). CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 39:191–8.
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Flockhart DA, Desta Z. (2011). In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab. Dispos 39:98–105.
   PubMed Web of Science ®Google Scholar
• Kassam JP, Tang BK, Kadar D, Kalow W. (1989). In vitro studies of human liver alcohol dehydrogenase variants using a variety of substrates. Drug Metab Dispos 17:567–72.
   PubMed Web of Science ®Google Scholar
• Kim JH, Sherman ME, Curriero FC, et al. (2004). Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 199:210–19.
   PubMed Web of Science ®Google Scholar
• Komen JC, Wanders RJ. (2006). Identification of the cytochrome P450 enzymes responsible for the omega-hydroxylation of phytanic acid. FEBS Lett 580:3794–8.
   PubMed Web of Science ®Google Scholar
• Lam JP, Mays DC, Lipsky JJ. (1997). Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. Biochemistry 36:13748–54.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216–37.
   PubMed Web of Science ®Google Scholar
• Linder CD, Renaud NA, Hutzler JM. (2009). Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 37:10–13.
   PubMed Web of Science ®Google Scholar
• Marill J, Cresteil T, Lanotte M, Chabot GG. (2000). Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 58:1341–8.
   PubMed Web of Science ®Google Scholar
• Matzke GR, Frye RF, Early JJ, et al. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182–90.
   PubMed Web of Science ®Google Scholar
• Mizuno-Yasuhira A, Nakai Y, Gunji E, et al. (2014). A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans. Drug Metab Dispos 42:1456–65.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Nakajima M, Yamanaka H, et al. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–4.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-Glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40.
   PubMed Web of Science ®Google Scholar
• Package Insert of Lusefi. (2015). Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400059_3969020F1020_1_06 [Japanese] [last accessed 8 Feb 2016].
   Google Scholar
• Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6.
   PubMed Web of Science ®Google Scholar
• Pavek P, Dvorak Z. (2008). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129–43.
   PubMed Web of Science ®Google Scholar
• Plosker GL. (2012). Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72:2289–312.
   PubMed Web of Science ®Google Scholar
• Poole RM, Dungo RT. (2014a). Ipragliflozin: first global approval. Drugs 74:611–17.
   PubMed Web of Science ®Google Scholar
• Poole RM, Prossler JE. (2014b). Tofogliflozin: first global approval. Drugs 74:939–44.
   PubMed Web of Science ®Google Scholar
• Santer R, Kinner M, Lassen CL, et al. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873–82.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. (2014). Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 31:345–61.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. (2015). Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial. Adv Ther 32:319–40.
   PubMed Web of Science ®Google Scholar
• Schweikl H, Taylor JA, Kitareewan S, et al. (1993). Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239–49.
   PubMedGoogle Scholar
• Scott LJ. (2014). Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74:1769–84.
   PubMed Web of Science ®Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. (2014). Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 30:1245–55.
   PubMed Web of Science ®Google Scholar
• Seino Y. (2014). Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15:2741–9.
   PubMed Web of Science ®Google Scholar
• Song IH, Borland J, Savina PM, et al. (2013). Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev 2:342–8.
   PubMed Web of Science ®Google Scholar
• Uchida S, Mitani A, Gunji E, et al. (2015). In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: inhibition kinetics and binding studies. J Pharmacol Sci 128:54–7.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–61.
   PubMed Web of Science ®Google Scholar
• Wang MZ, Saulter JY, Usuki E, et al. (2006). CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 34:1985–94.
   PubMed Web of Science ®Google Scholar
• Wang MZ, Wu JQ, Bridges AS, et al. (2007). Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos 35:2067–75.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hall SD, Maya JF, et al. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77–85.
   PubMed Web of Science ®Google Scholar
• Wright EM. (2001). Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280:F10–18.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Uchida S, Kitano K, et al. (2011). TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164:181–91.
   PubMed Web of Science ®Google Scholar
• Yamane M, Kawashima K, Yamaguchi K, et al. (2015). In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica 45:230–8.
   PubMed Web of Science ®Google Scholar
• Zhang H, Davis CD, Sinz MW, Rodrigues AD. (2007). Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–87.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Wang Y, Prakash C. (2006). Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7:939–48.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Zhao P, Huang SM. (2009). Predicting drug-drug interactions: an FDA perspective. AAPS J 11:300–6.
   PubMed Web of Science ®Google Scholar